Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy
(SABR), has emerged as one of the standard treatment options for stage I non-small cell …

Aim To review key studies evaluating stereotactic radiotherapy in the setting of early-stage
non-small cell lung cancer (NSCLC) for inoperable or high-risk patients, and discuss areas …

Introduction. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung
cancer (NSCLC) is now an accepted and patient friendly treatment, but still controversy …

The standard of care for early-stage lung cancer is surgical resection. Many patients with this
diagnosis have comorbidities that preclude oncologic resection. Randomized data show that …

Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has
been developed as an innovative therapy for stage I non-small cell lung cancer and has now …

Stereotactic body radiotherapy (SBRT) is a success story. After originally being intended for
the curative treatment of peripheral small volume, medically inoperable stage I NSCLC, the …

For decades, surgery was considered to be the only standard therapy for early-stage non-
small-cell lung cancer (NSCLC). However stereotactic ablative body radiotherapy (SABR) …

Stereotactic ablative radiotherapy (SABR), also known as “stereotactic body radiation
therapy”(SBRT), has revolutionized the treatment of early-stage non-small cell lung cancer …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the
United States, but as lung cancer screening expands to include younger patients with …

In this manuscript, developments in the techniques, clinical outcome, toxicity, and future
perspectives of SBRT for medically inoperable and operable early stage NCSLC are …